Lonza, a producer of organic fine chemicals, biocides, active ingredients, and biotechnology products, agreed to acquire Genentech large-scale biologics manufacturing site from Roche, a developer and manufacturer of pharmaceutical and diagnostic products, for $1.2bn. “The Vacaville site is a highly valuable strategic acquisition that will make capacity immediately available for our customers and unlock future growth for our Biologics division. It will support us in providing a commercialization path to existing customers and incremental large-scale commercial capacity to our partners. We have deep and long-standing industrial expertise in delivering commercial scale manufacturing services for our customers’ therapies. In combining this with the strong legacy of the Vacaville facility, its highly skilled colleague community and its proven track record on quality, we are excited to take our leading large-scale mammalian offering to its next chapter of growth,” Jean-Christophe Hyvert, Lonza President.